Dealing with loss: food and eating in women with ovarian cancer on parenteral nutrition

Abstract

The lead author affirms that this manuscript is an honest, accurate and transparent account of the study being reported. The lead author affirms that no important aspects of the study have been omitted and that any discrepancies from the study as planned have been explained.

Symptom burden and lived experiences of patients, caregivers and healthcare professionals on the management of malignant bowel obstruction: A qualitative systematic review

“…Four papers (reporting on two studies), offered patient, caregiver, and healthcare professional perspectives on the following interventions; percutaneous venting gastrostomy/gastrojejunostomy and home parenteral nutrition. 30 – 33 One other paper looked at patients’ experiences of a self-management intervention; an educational tool to educate patients on malignant bowel obstruction. 25…”

“… 31 Other negative aspects included patients considering a venting gastrostomy/gastrojejunostomy as a constant presence; some were afraid to eat, for fear of causing a blockage of the tube. 31 , 32 …”

“… 27 While some patients still held on to the hope that there may be a cure, most patients reported more realistic goals for themselves, such as being pain free, able to spend time with family ( “spending time with family when you get to, like, my stage, is the most important” Patient, page 6 ) 31 and having a sense of normality: it’s just wanting to get back to normal, if you see what I mean, whatever normal is these days.” Patient, page 4 . 32 …”

“… 27 Family mealtimes and most social events revolve around eating and/or drinking, thereby resulting in impacts on the patient and the family. 28 , 32 such as reduced social interactions: “I can’t meet my friends for a drink now and I miss them. .…”

Glucagon-like peptide 2 analogues in the treatment of intestinal failure: A qualitative exploration of the views of patients and their families in decision making

“…The decision by patients to try teduglutide may not be straightforward. One study using questionnaires investigated patient QoL whilst on teduglutide and found it improved over the 24 week study period [20]. It was suggested that this improvement was related to a reduction in PN volume but there was no significant difference in QoL between the teduglutide and placebo groups; although this could have related to the short duration of the study or the tool used to measure QoL [20].…”